Revance Therapeutics (NASDAQ:RVNC – Get Rating) and Nanobiotix (NASDAQ:NBTX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.
This is a summary of current ratings for Revance Therapeutics and Nanobiotix, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Revance Therapeutics and Nanobiotix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Revance Therapeutics and Nanobiotix’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Revance Therapeutics||$77.80 million||14.15||-$281.31 million||($4.04)||-3.75|
|Nanobiotix||$3.13 million||40.84||-$55.61 million||N/A||N/A|
Nanobiotix has lower revenue, but higher earnings than Revance Therapeutics.
Institutional and Insider Ownership
79.9% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 11.3% of Nanobiotix shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
Revance Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
Revance Therapeutics beats Nanobiotix on 7 of the 12 factors compared between the two stocks.
Revance Therapeutics Company Profile (Get Rating)
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Nanobiotix Company Profile (Get Rating)
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.